Laboratory studies evaluating the efficacy of a novel orally administered combination product containing sarolaner, moxidectin and pyrantel (Simparica Trio™) for the treatment and control of flea infestations on dogs

Table 1 Arithmetic mean flea counts and percent efficacy relative to placebo at 24 h after treatment and weekly re-infestations with Ctenocephalides felis or C. canis for dogs treated orally with Simparica Trio™

Day after treatment	Treatment group	Study 1 (C. felis)		Study 3 (C. canis)
Day after treatment	Treatment group	Flea count	% Efficacy	Flea count	% Efficacy
1	Placebo	89.5		85.5
1	Simparica Trio™	0.1*	99.9	0*	100
7	Placebo	78.5		74.8
7	Simparica Trio™	0*	100	0*	100
14	Placebo	82.8		75.3
14	Simparica Trio™	0*	100	0*	100
21	Placebo	80.5		87.9
21	Simparica Trio™	0*	100	0*	100
28	Placebo	88.1		81.8
28	Simparica Trio™	0*	100	0*	100
35	Placebo	89.5		75.3
35	Simparica Trio™	0*	100	0*	100

*Flea counts are significantly lower than placebo; 14.45 ≤ t_df ≤ 34.43, 7 ≤ df ≤14, P < 0.0001

ISSN: 1756-3305